1. Establishment and genetic characterization of cell lines derived from proliferating nasal polyps and sinonasal inverted papillomas.
- Author
-
Nukpook T, Ekalaksananan T, Kiyono T, Kasemsiri P, Teeramatwanich W, Vatanasapt P, Chaiwiriyakul S, Ungarreevittaya P, Kampan J, Muisuk K, and Pientong C
- Subjects
- Adolescent, Aged, Cell Line, Tumor, Cell Proliferation, Cells, Cultured, Child, Cyclin D1 genetics, Cyclin D1 metabolism, Cyclin-Dependent Kinase 4 genetics, Cyclin-Dependent Kinase 4 metabolism, Humans, Male, Microsatellite Repeats, Nasal Polyps pathology, Nose Neoplasms pathology, Papilloma, Inverted pathology, Telomerase genetics, Telomerase metabolism, Transduction, Genetic methods, Cell Culture Techniques methods, Nasal Polyps genetics, Nose Neoplasms genetics, Papilloma, Inverted genetics
- Abstract
To better understand the pathogenesis of nasal polyps (NPs) and sinonasal inverted papillomas (SIPs), we aimed to establish cell lines from fresh tissues of NPs and SIPs and characterize them. Primary cell cultures were obtained from two NP tissues (NP2 and NP3) and one SIP tissue (IP4). All the cells were polygonal in shape, expressed cytokeratin 14, and had normal diploid chromosome status. HPV58 DNA was detected in NP3. To obtain immortal primary cells, NP2 and IP4 cells were transduced with a combination of mutant CDK4, cyclinD1 and TERT. These cells were thereafter named NP2/K4DT and IP4/K4DT, respectively. HPV58-positive NP3 cells were transduced with TERT alone, the resulting cells named NP3/T. Phenotypic and genotypic identity of original tissues and derived cells was investigated. All the cell cultures with transgenes were confirmed to be derived from their parental cells and primary tumor tissues by analysis of short tandem repeats (STR) and maintained in vitro growth, genetic profiles and gene expression characteristics of the primary cells. These virtually immortalized cells, as well as the primary cells, have potential as in vitro models for studying the pathogenesis of NPs and SIPs and for preclinical study to develop new therapeutic agents., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF